Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic 'sensor/effector' compounds

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1407-1411

  Lilienthal, Nils ^a   Prinz, Christian ^a   Peer Zada, Abdul A ^a,c   Doering, Mandy ^b   Ba, Lalla A ^b   Hallek, Michael ^a   Jacob, Claus ^b   Herling, Marco ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

CLL; organochalcogens; oxidative stress; redox catalysts; ROS

Indexed keywords

DNA; FLUDARABINE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CATALYSIS; CELL SURVIVAL; DRUG SYNERGISM; GLUTATHIONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; ORGANIC CHEMICALS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; VIDARABINE;

EID: 79959626724     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.568077     Document Type: Article

References (15)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
2. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. Oxford: Oxford University Press; 2007.
3. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al. Oxidative stress in cancer associated fibroblasts drives tumorstroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010;9:3256-3276.
4. Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 2010;40:323-332.
5. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-591.
6. Biswas S, Zhao X, Mone AP, et al. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res 2010;34:925-931.
7. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003;101:4098-4104. (Pubitemid 36857891)
8. Jamier V, Ba LA, Jacob C. Selenium- and tellurium-containing multifunctional redox agents as biochemical redox modulators with selective cytotoxicity. Chemistry 2010;16: 10920-10928.
9. Doering M, Ba LA, Lilienthal N, et al. Synthesis and selective anticancer activity of organochalcogen based redox catalysts. J Med Chem 2010;53:6954-6963.
10. Calissano C, Damle RN, Hayes G, et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009;114:4832-4842.
11. Djurdjevic P, Zelen I, Ristic P, et al. Oxidative stress accelerates spontaneous apoptosis of B-chronic lymphocytic leukemia lymphocytes. J BUON 2009;14:281-287.
12. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110. (Pubitemid 38736063)
13. Ryan EP, Bushnell TP, Friedman AE, Rahman I, Phipps RP. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol Immunother 2008;57:347-358. (Pubitemid 350301954)
14. Achanta G, Sasaki R, Feng L, et al. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J 2005;24:3482-3492. (Pubitemid 41486785)
15. Trachootham D, Zhang H, Zhang W, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008;112: 1912-1922.